Welcome to our dedicated page for Harrow Health news (Ticker: HROW), a resource for investors and traders seeking the latest updates and insights on Harrow Health stock.
Harrow, Inc. (Nasdaq: HROW) is an ophthalmic-focused pharmaceutical company that regularly issues news and updates related to its portfolio of eye-care products, development programs, and corporate activities. The company describes itself as a leading provider of ophthalmic disease management solutions in North America, with products that address conditions such as dry eye disease, wet age-related macular degeneration, cataracts, refractive errors, glaucoma, ocular surface conditions, and retina diseases.
News about Harrow commonly covers financial results and investor communications, including quarterly earnings releases, letters to stockholders, and conference call announcements. The company also announces participation in investor conferences and Investor & Analyst Day events, where it provides overviews of its commercial portfolio, pipeline, and long-term vision.
Another key theme in Harrow’s news flow is business development and pipeline progress. Recent press releases have described the agreement to acquire, and subsequent closing of the acquisition of, Melt Pharmaceuticals, Inc., a clinical-stage company developing non-opioid, non-IV sedation therapies such as MELT-300 and MELT-210. Harrow has used these announcements to explain the strategic rationale for expanding into procedural sedation and to outline regulatory and development milestones for these product candidates.
Harrow’s news also highlights access and affordability initiatives, such as the launch of the VEVYE Access for All (VAFA) program for VEVYE (cyclosporine ophthalmic solution) 0.1% and the broader Harrow Access for All (HAFA) program, which is intended to extend a unified access model across its branded, authorized generics, and compounded ophthalmic medications. Additional releases address leadership changes at ImprimisRx, debt offerings and related credit facilities, and other corporate matters.
Investors and eyecare professionals reviewing Harrow’s news page can expect updates on earnings, capital markets transactions, acquisitions, development milestones for ophthalmic and procedural sedation candidates, and initiatives aimed at improving patient access to the company’s ophthalmic therapies.
Harrow Health, Inc. (NASDAQ: HROW) has launched a public offering of $25 million in senior notes due 2026, pending market conditions. The notes received a "BB" rating from Egan-Jones Ratings Company. Proceeds are intended to repay $15.5 million of outstanding borrowings under a term loan and for general corporate purposes including strategic acquisitions and working capital. The offering is made under an effective SEC registration statement. B. Riley Securities and others are managing the offering.
Harrow Health, Inc. (NASDAQ: HROW) reported preliminary unaudited financial results for Q1 2021, estimating total revenue between $14.9 million and $15.5 million with an Adjusted EBITDA exceeding $2.7 million. As of March 31, 2021, the company had approximately $6.5 million in cash and cash equivalents, which increased by $10.6 million from the sale of shares in Eton Pharmaceuticals. The final results will be announced on May 11, 2021.
Harrow Health (NASDAQ: HROW) reported a strong fourth quarter of 2020 with revenues of $14.6 million, marking a 16% increase from $12.6 million in the previous year. Adjusted EBITDA hit a record $4.0 million, up from $2.1 million year-over-year. Operating income rose to $2.6 million compared to $0.9 million in Q4 2019, while gross margins remained stable at 73%. The increase in revenue was attributed in part to $349,000 in Dexycu® commissions. CEO Mark L. Baum noted the company's resilience amid challenges and expressed optimism about future growth.
Harrow Health, Inc. (NASDAQ: HROW) announced participation in the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021. CEO Mark Baum and CFO Andrew Boll will engage in a virtual presentation available on the company's investor relations site starting March 9, 2021, at 7:00 a.m. ET, archived for 90 days. The management team will also hold one-on-one meetings via H.C. Wainwright. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leader in ophthalmology outsourcing and pharmaceutical compounding.
Harrow Health, Inc. (NASDAQ: HROW) announced it will release its fourth quarter and annual financial results for the year ending December 31, 2020, on March 8, 2021, after the market close. The financial results will be available on their website, and a conference call will occur at 4:45 p.m. ET to discuss the outcomes and present a business update. Harrow Health specializes in ophthalmic healthcare and owns ImprimisRx, a leading ophthalmology outsourcing business.
Melt Pharmaceuticals announced positive results from its Phase 1 MELT study, which evaluated the pharmacokinetic parameters of its novel midazolam and ketamine formulation. The study met its objectives, demonstrating good tolerance and relative bioavailability. The company plans to meet with the FDA to finalize its clinical protocol and commence a Phase 2 study in the third quarter of 2021, targeting cataract surgery patients. If approved, this non-opioid and IV-free option could significantly change pain management during surgeries.
Harrow Health (NASDAQ: HROW) announced a study published in the AANA Journal demonstrating the effectiveness of its MKO Melt® troche as a non-opioid alternative for IV sedation in cataract surgeries. The study involved 107 patients, comparing MKO Melt to traditional sedation methods. Findings indicated comparable comfort levels between both sedation methods, promoting MKO Melt for patients, especially those with needle-phobia. The MKO Melt has been used in over 250,000 cataract surgeries and is available for purchase through ImprimisRx.
Harrow Health (NASDAQ: HROW) will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference from December 1-3, 2020. CEO Mark Baum and CFO Andrew Boll will present a corporate overview, with the management team available for one-on-one meetings. The pre-recorded presentation will be accessible to registered attendees from November 23 until December 3. Additionally, a replay of the conference presentation will be available for approximately 90 days on Harrow’s website.
Harrow Health (NASDAQ: HROW) reported exceptional financial results for Q3 2020, marking the best quarter in its history. Revenues increased month-over-month, achieving record gross margins and adjusted EBITDA. CEO Mark L. Baum expressed optimism about a continuous upward revenue trend heading into 2021, anticipating potential value inflection events. The company primarily focuses on ophthalmology through ImprimisRx and owns significant stakes in several pharmaceutical entities. A conference call discussing these results will be held on Nov. 9, 2020.
Harrow Health (NASDAQ: HROW) will announce its third quarter 2020 financial results after the market closes on November 9, 2020. A conference call will follow at 4:45 p.m. EST, providing an overview of the quarter and future outlook. Investors can access a press release and the company's Letter to Stockholders on its Investor Relations website. The call is intended for analysts to engage with the management team. Replay options for the call will be available until December 9, 2020, for dial-in listeners and until February 9, 2021, for webcast listeners.